Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment
A Crossover, Randomized Block Sequence, Double-Blind, Placebo-Controlled Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment in Aging
Sponsor: Steven E Arnold, MD
Listed as NCT04078178, this NA trial focuses on Cognition Disorders in Old Age and Cognitive Decline and remains completed. Sponsored by Steven E Arnold, MD, it has been updated 14 times since 2020, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Dec 2024 — Present [monthly]
Completed NA
-
Sep 2024 — Dec 2024 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
May 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 9 earlier versions
-
Mar 2022 — May 2022 [monthly]
Recruiting NA
-
Oct 2021 — Mar 2022 [monthly]
Recruiting NA
-
Jan 2021 — Oct 2021 [monthly]
Recruiting NA
-
Dec 2020 — Jan 2021 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Aug 2020 — Dec 2020 [monthly]
Not Yet Recruiting NA
-
Jun 2020 — Aug 2020 [monthly]
Not Yet Recruiting NA
-
Mar 2020 — Jun 2020 [monthly]
Not Yet Recruiting NA
-
Feb 2020 — Mar 2020 [monthly]
Not Yet Recruiting NA
-
Oct 2019 — Feb 2020 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Steven E Arnold, MD
For direct contact, visit the study record on ClinicalTrials.gov .